TREVI THERAPEUTICS INC (TRVI) Stock Income Statement
NASDAQ:TRVI - Nasdaq - US89532M1018 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 50.00M | 52.00M | 34.00M | 29.91M | 32.48M | |||
| Research and Development | 38.38M | 39.38M | 23.68M | 19.83M | 22.98M | |||
| Selling, General, and Administrative Expenses | 12.71M | 12.00M | 10.00M | 10.07M | 9.49M | |||
| Operating Income | -50.00M | -52.00M | -34.00M | -29.91M | -32.48M | |||
| Interest Income/Expense | 3.73M | 3.60M | 4.36M | 430.00K | -1.11M | |||
| Other Income/Expense | -30.00K | -20.00K | 470.00K | 290.00K | -380.00K | |||
| Income Before Taxes | -46.00M | -48.00M | -29.00M | -29.19M | -33.96M | |||
| Income Tax | -30.00K | -30.00K | -30.00K | -40.00K | -20.00K | |||
| Net Income | -46.00M | -48.00M | -29.00M | -29.15M | -33.94M | |||
| EBITDA | -49.85M | -51.85M | -33.88M | -29.87M | -32.43M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.45 | -0.47 | -0.29 | -0.45 | -1.49 | |||
| Non GAAP EPS | -0.45 | -0.47 | -0.29 | -0.56 | -1.52 | |||
| Statistics | ||||||||
All data in USD